| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Vaccination | 41 | 2021 | 19050 | 2.72 | Why? |
| Whooping Cough | 5 | 2019 | 201 | 2.22 | Why? |
| Compensation and Redress | 3 | 2020 | 49 | 2.07 | Why? |
| Vaccination Coverage | 6 | 2019 | 1249 | 1.92 | Why? |
| Vaccines | 17 | 2021 | 3692 | 1.84 | Why? |
| Immunization | 8 | 2021 | 2019 | 1.63 | Why? |
| Parents | 11 | 2019 | 2758 | 1.61 | Why? |
| Patient Acceptance of Health Care | 13 | 2021 | 5002 | 1.57 | Why? |
| Immunization Programs | 9 | 2021 | 2006 | 1.55 | Why? |
| Papillomavirus Vaccines | 3 | 2019 | 405 | 1.45 | Why? |
| Respiratory Syncytial Virus Vaccines | 2 | 2019 | 104 | 1.43 | Why? |
| Pertussis Vaccine | 3 | 2017 | 89 | 1.29 | Why? |
| Mandatory Programs | 2 | 2020 | 291 | 1.15 | Why? |
| Behavior Therapy | 2 | 2018 | 235 | 1.09 | Why? |
| Religion | 2 | 2018 | 353 | 1.05 | Why? |
| Measles | 4 | 2019 | 608 | 1.03 | Why? |
| Counseling | 2 | 2018 | 747 | 0.92 | Why? |
| Child Day Care Centers | 2 | 2021 | 208 | 0.91 | Why? |
| Informed Consent By Minors | 1 | 2019 | 14 | 0.81 | Why? |
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2019 | 91 | 0.80 | Why? |
| Respiratory Syncytial Virus Infections | 2 | 2019 | 1234 | 0.78 | Why? |
| Behavior | 1 | 2021 | 252 | 0.73 | Why? |
| Immunity, Herd | 3 | 2021 | 1011 | 0.73 | Why? |
| Child Care | 1 | 2020 | 209 | 0.73 | Why? |
| Respiratory Syncytial Viruses | 2 | 2019 | 612 | 0.72 | Why? |
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 92 | 0.71 | Why? |
| Health Behavior | 4 | 2022 | 4449 | 0.70 | Why? |
| Vaccination Refusal | 4 | 2019 | 831 | 0.68 | Why? |
| Catholicism | 1 | 2017 | 64 | 0.65 | Why? |
| Immunity, Maternally-Acquired | 1 | 2018 | 179 | 0.64 | Why? |
| Adverse Drug Reaction Reporting Systems | 2 | 2019 | 694 | 0.60 | Why? |
| Influenza Vaccines | 5 | 2019 | 2941 | 0.59 | Why? |
| Meningococcal Vaccines | 1 | 2018 | 225 | 0.58 | Why? |
| Pregnancy | 17 | 2021 | 23879 | 0.57 | Why? |
| Attitude to Health | 5 | 2021 | 2002 | 0.56 | Why? |
| Antibodies, Bacterial | 1 | 2018 | 510 | 0.55 | Why? |
| Drug Approval | 2 | 2021 | 1325 | 0.55 | Why? |
| United States | 23 | 2022 | 46150 | 0.54 | Why? |
| Hospitals, Community | 1 | 2019 | 475 | 0.54 | Why? |
| Veterans | 2 | 2021 | 1131 | 0.53 | Why? |
| Herpes Zoster | 1 | 2019 | 331 | 0.51 | Why? |
| Ships | 1 | 2021 | 1046 | 0.50 | Why? |
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 8811 | 0.50 | Why? |
| Pregnant Women | 4 | 2019 | 2535 | 0.50 | Why? |
| Mobile Applications | 2 | 2019 | 3032 | 0.47 | Why? |
| Influenza, Human | 6 | 2020 | 10779 | 0.46 | Why? |
| Morals | 1 | 2017 | 483 | 0.46 | Why? |
| Information Systems | 1 | 2013 | 110 | 0.45 | Why? |
| Orthomyxoviridae | 1 | 2020 | 1168 | 0.45 | Why? |
| Patient Education as Topic | 2 | 2019 | 1476 | 0.45 | Why? |
| Infant | 18 | 2019 | 30274 | 0.44 | Why? |
| Liability, Legal | 3 | 2020 | 198 | 0.44 | Why? |
| Georgia | 4 | 2019 | 955 | 0.43 | Why? |
| Health Policy | 6 | 2021 | 6242 | 0.43 | Why? |
| Pneumonia, Bacterial | 1 | 2018 | 843 | 0.43 | Why? |
| Health Care Costs | 1 | 2019 | 1007 | 0.42 | Why? |
| Washington | 4 | 2020 | 1722 | 0.41 | Why? |
| California | 4 | 2018 | 2047 | 0.41 | Why? |
| Humans | 89 | 2022 | 930598 | 0.40 | Why? |
| Databases, Factual | 4 | 2020 | 6248 | 0.40 | Why? |
| Waste Water | 1 | 2020 | 2185 | 0.39 | Why? |
| Uterine Cervical Neoplasms | 1 | 2018 | 842 | 0.39 | Why? |
| Papillomavirus Infections | 1 | 2018 | 861 | 0.38 | Why? |
| Colorado | 3 | 2019 | 434 | 0.37 | Why? |
| Maternal Health Services | 1 | 2018 | 808 | 0.37 | Why? |
| Immunization Schedule | 4 | 2019 | 1305 | 0.36 | Why? |
| Cost of Illness | 1 | 2019 | 1903 | 0.35 | Why? |
| Information Dissemination | 2 | 2021 | 2986 | 0.34 | Why? |
| Health Education | 2 | 2017 | 1539 | 0.34 | Why? |
| Child, Preschool | 11 | 2020 | 36283 | 0.34 | Why? |
| Health Promotion | 1 | 2021 | 2020 | 0.34 | Why? |
| Politics | 1 | 2020 | 1824 | 0.33 | Why? |
| Adolescent | 15 | 2021 | 86841 | 0.32 | Why? |
| Health Communication | 1 | 2017 | 1120 | 0.31 | Why? |
| Infant, Newborn | 12 | 2020 | 23105 | 0.31 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.30 | Why? |
| Communicable Diseases | 1 | 2020 | 2148 | 0.29 | Why? |
| Communicable Disease Control | 6 | 2021 | 29620 | 0.28 | Why? |
| Pandemics | 20 | 2022 | 389249 | 0.28 | Why? |
| Pakistan | 5 | 2019 | 2302 | 0.28 | Why? |
| Female | 42 | 2021 | 380317 | 0.27 | Why? |
| Public Health | 4 | 2020 | 16359 | 0.27 | Why? |
| Adult | 27 | 2022 | 244371 | 0.27 | Why? |
| Child | 14 | 2021 | 70012 | 0.26 | Why? |
| Decision Making | 2 | 2017 | 3132 | 0.26 | Why? |
| Young Adult | 16 | 2021 | 93724 | 0.26 | Why? |
| Infectious Disease Transmission, Vertical | 2 | 2019 | 5164 | 0.24 | Why? |
| Guatemala | 2 | 2018 | 106 | 0.24 | Why? |
| Seasons | 5 | 2021 | 4071 | 0.23 | Why? |
| Viral Vaccines | 2 | 2020 | 7560 | 0.23 | Why? |
| Disease Outbreaks | 7 | 2021 | 27595 | 0.23 | Why? |
| Communication | 3 | 2020 | 5206 | 0.23 | Why? |
| Connecticut | 2 | 2020 | 547 | 0.23 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.23 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.22 | Why? |
| Pneumonia, Viral | 12 | 2020 | 243684 | 0.21 | Why? |
| Asthma | 1 | 2019 | 4383 | 0.21 | Why? |
| Health Personnel | 5 | 2021 | 29646 | 0.21 | Why? |
| Famous Persons | 1 | 2020 | 74 | 0.20 | Why? |
| Personal Space | 1 | 2020 | 96 | 0.20 | Why? |
| Pregnancy Complications, Infectious | 5 | 2021 | 11559 | 0.20 | Why? |
| Global Health | 3 | 2020 | 13911 | 0.19 | Why? |
| Streptococcus | 1 | 2019 | 76 | 0.19 | Why? |
| Betacoronavirus | 9 | 2020 | 204454 | 0.19 | Why? |
| Surveys and Questionnaires | 8 | 2021 | 43792 | 0.19 | Why? |
| Students | 1 | 2017 | 5255 | 0.19 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.18 | Why? |
| Chickenpox Vaccine | 1 | 2019 | 59 | 0.18 | Why? |
| Mali | 1 | 2018 | 181 | 0.18 | Why? |
| New South Wales | 1 | 2019 | 336 | 0.18 | Why? |
| Smallpox | 1 | 2019 | 96 | 0.18 | Why? |
| Mothers | 2 | 2019 | 1624 | 0.18 | Why? |
| Injection Site Reaction | 1 | 2019 | 124 | 0.17 | Why? |
| Risk Assessment | 1 | 2022 | 25439 | 0.17 | Why? |
| Rubella | 1 | 2019 | 127 | 0.17 | Why? |
| Age of Onset | 1 | 2019 | 557 | 0.17 | Why? |
| Herpes Zoster Vaccine | 1 | 2019 | 112 | 0.17 | Why? |
| Seizures, Febrile | 1 | 2017 | 59 | 0.17 | Why? |
| Practice Guidelines as Topic | 2 | 2019 | 15421 | 0.17 | Why? |
| History, 19th Century | 1 | 2019 | 384 | 0.17 | Why? |
| Dried Blood Spot Testing | 1 | 2020 | 383 | 0.17 | Why? |
| Biotechnology | 1 | 2020 | 444 | 0.16 | Why? |
| Freedom | 1 | 2017 | 110 | 0.16 | Why? |
| Social Perception | 1 | 2020 | 371 | 0.16 | Why? |
| Infant, Low Birth Weight | 1 | 2018 | 243 | 0.16 | Why? |
| Factor Analysis, Statistical | 1 | 2019 | 538 | 0.16 | Why? |
| Cluster Analysis | 3 | 2020 | 3001 | 0.16 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.16 | Why? |
| Product Surveillance, Postmarketing | 1 | 2019 | 189 | 0.16 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2019 | 282 | 0.16 | Why? |
| Financing, Personal | 1 | 2017 | 113 | 0.15 | Why? |
| Ghana | 1 | 2019 | 763 | 0.15 | Why? |
| Male | 27 | 2021 | 367725 | 0.15 | Why? |
| Vaccines, Conjugate | 1 | 2018 | 328 | 0.15 | Why? |
| Developing Countries | 3 | 2021 | 4283 | 0.15 | Why? |
| Chickenpox | 1 | 2019 | 194 | 0.15 | Why? |
| Confidence Intervals | 1 | 2018 | 744 | 0.14 | Why? |
| Multiplex Polymerase Chain Reaction | 2 | 2020 | 1439 | 0.14 | Why? |
| Inventions | 1 | 2019 | 372 | 0.14 | Why? |
| Drug Utilization | 1 | 2020 | 619 | 0.14 | Why? |
| Sewage | 1 | 2020 | 591 | 0.14 | Why? |
| Random Allocation | 1 | 2017 | 773 | 0.14 | Why? |
| Public Sector | 1 | 2017 | 204 | 0.14 | Why? |
| Critical Care | 1 | 2018 | 14081 | 0.14 | Why? |
| Schools | 3 | 2019 | 4187 | 0.14 | Why? |
| Private Sector | 1 | 2017 | 262 | 0.14 | Why? |
| Nepal | 1 | 2018 | 1004 | 0.13 | Why? |
| Regression Analysis | 1 | 2021 | 2484 | 0.13 | Why? |
| Community Participation | 1 | 2020 | 605 | 0.13 | Why? |
| Fetal Blood | 1 | 2017 | 573 | 0.13 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.13 | Why? |
| Government Regulation | 1 | 2020 | 842 | 0.12 | Why? |
| Pneumococcal Vaccines | 1 | 2018 | 571 | 0.12 | Why? |
| Advisory Committees | 1 | 2020 | 1418 | 0.12 | Why? |
| Organizational Policy | 1 | 2018 | 694 | 0.12 | Why? |
| Disease Eradication | 1 | 2019 | 581 | 0.12 | Why? |
| Professional-Family Relations | 1 | 2017 | 424 | 0.12 | Why? |
| Gestational Age | 1 | 2018 | 1488 | 0.12 | Why? |
| Stillbirth | 1 | 2017 | 544 | 0.12 | Why? |
| Cross-Sectional Studies | 8 | 2021 | 53120 | 0.12 | Why? |
| Sex Characteristics | 1 | 2020 | 1120 | 0.12 | Why? |
| Pneumococcal Infections | 1 | 2018 | 562 | 0.12 | Why? |
| Information Seeking Behavior | 1 | 2019 | 539 | 0.12 | Why? |
| History, 21st Century | 1 | 2019 | 1849 | 0.11 | Why? |
| Financing, Government | 1 | 2017 | 434 | 0.11 | Why? |
| United States Food and Drug Administration | 1 | 2019 | 1276 | 0.11 | Why? |
| Incidence | 5 | 2020 | 25622 | 0.11 | Why? |
| Time Factors | 5 | 2021 | 31397 | 0.11 | Why? |
| Hepatitis B | 1 | 2019 | 888 | 0.11 | Why? |
| Government | 1 | 2020 | 1453 | 0.11 | Why? |
| Adjuvants, Immunologic | 1 | 2020 | 1709 | 0.11 | Why? |
| Immunization, Secondary | 1 | 2019 | 1649 | 0.11 | Why? |
| Cooperative Behavior | 1 | 2019 | 1216 | 0.11 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.11 | Why? |
| Policy Making | 1 | 2018 | 829 | 0.10 | Why? |
| Gynecology | 1 | 2018 | 741 | 0.10 | Why? |
| Postpartum Period | 1 | 2017 | 936 | 0.10 | Why? |
| Recurrence | 1 | 2020 | 3675 | 0.10 | Why? |
| Reagent Kits, Diagnostic | 1 | 2020 | 2149 | 0.10 | Why? |
| Public Opinion | 1 | 2020 | 1165 | 0.10 | Why? |
| Cohort Studies | 5 | 2021 | 36005 | 0.10 | Why? |
| Risk | 2 | 2019 | 5288 | 0.10 | Why? |
| Hand Hygiene | 1 | 2020 | 1493 | 0.10 | Why? |
| Culture | 1 | 2013 | 370 | 0.10 | Why? |
| Newspapers as Topic | 1 | 2011 | 134 | 0.10 | Why? |
| Epidemiological Monitoring | 2 | 2020 | 3493 | 0.10 | Why? |
| Biomedical Research | 3 | 2021 | 5270 | 0.09 | Why? |
| Obstetrics | 1 | 2018 | 859 | 0.09 | Why? |
| Basic Reproduction Number | 1 | 2020 | 2676 | 0.09 | Why? |
| Patients | 1 | 2017 | 1167 | 0.09 | Why? |
| Drug Industry | 1 | 2017 | 689 | 0.09 | Why? |
| Adaptive Immunity | 1 | 2020 | 2585 | 0.09 | Why? |
| Leukocyte Count | 1 | 2018 | 3178 | 0.09 | Why? |
| Perception | 1 | 2020 | 2827 | 0.09 | Why? |
| Prenatal Care | 1 | 2019 | 1314 | 0.09 | Why? |
| Needs Assessment | 1 | 2019 | 2352 | 0.09 | Why? |
| Parenting | 1 | 2014 | 486 | 0.09 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.09 | Why? |
| South Africa | 1 | 2018 | 3326 | 0.09 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.09 | Why? |
| Public Policy | 1 | 2020 | 1894 | 0.09 | Why? |
| Immunocompromised Host | 2 | 2021 | 5150 | 0.08 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.08 | Why? |
| Logistic Models | 3 | 2021 | 9089 | 0.08 | Why? |
| Lymphocyte Count | 1 | 2018 | 4758 | 0.08 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.08 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.08 | Why? |
| Patient Satisfaction | 1 | 2019 | 2517 | 0.08 | Why? |
| World Health Organization | 1 | 2019 | 4213 | 0.08 | Why? |
| Premature Birth | 1 | 2018 | 2151 | 0.08 | Why? |
| T-Lymphocytes | 2 | 2020 | 6670 | 0.08 | Why? |
| Pharmacists | 1 | 2017 | 1246 | 0.08 | Why? |
| Research | 1 | 2019 | 2115 | 0.08 | Why? |
| Age Factors | 4 | 2020 | 21039 | 0.07 | Why? |
| Rural Population | 1 | 2018 | 2408 | 0.07 | Why? |
| Smartphone | 1 | 2017 | 1840 | 0.07 | Why? |
| Australia | 1 | 2018 | 6306 | 0.07 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.07 | Why? |
| Nasopharynx | 2 | 2020 | 10224 | 0.07 | Why? |
| Clinical Trials as Topic | 2 | 2021 | 7330 | 0.07 | Why? |
| Fear | 1 | 2019 | 3607 | 0.07 | Why? |
| Skin Diseases | 1 | 2020 | 2509 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.07 | Why? |
| Polymerase Chain Reaction | 1 | 2018 | 6740 | 0.06 | Why? |
| Socioeconomic Factors | 2 | 2018 | 8495 | 0.06 | Why? |
| Health Status | 1 | 2017 | 3259 | 0.06 | Why? |
| Germany | 1 | 2018 | 9196 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.06 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.06 | Why? |
| Europe | 1 | 2019 | 12702 | 0.06 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.06 | Why? |
| France | 1 | 2018 | 12074 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.06 | Why? |
| Universities | 1 | 2017 | 4374 | 0.06 | Why? |
| Population Surveillance | 1 | 2018 | 4967 | 0.06 | Why? |
| African Americans | 1 | 2017 | 3363 | 0.06 | Why? |
| Aged | 8 | 2021 | 215776 | 0.06 | Why? |
| Travel | 1 | 2020 | 7220 | 0.05 | Why? |
| Healthcare Disparities | 1 | 2019 | 3893 | 0.05 | Why? |
| Masks | 2 | 2021 | 8528 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.05 | Why? |
| Interleukin-5 | 1 | 2020 | 138 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.05 | Why? |
| Internet | 1 | 2017 | 6204 | 0.05 | Why? |
| Hypertension | 1 | 2021 | 8895 | 0.05 | Why? |
| Interleukin-13 | 1 | 2020 | 204 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.05 | Why? |
| Social Norms | 1 | 2020 | 240 | 0.04 | Why? |
| Likelihood Functions | 1 | 2020 | 719 | 0.04 | Why? |
| Economics | 1 | 2019 | 196 | 0.04 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.04 | Why? |
| Immunoglobulin E | 1 | 2020 | 557 | 0.04 | Why? |
| Infant Mortality | 1 | 2019 | 268 | 0.04 | Why? |
| Sample Size | 1 | 2018 | 518 | 0.04 | Why? |
| Serogroup | 1 | 2018 | 510 | 0.04 | Why? |
| Public Health Surveillance | 2 | 2020 | 3129 | 0.04 | Why? |
| Mediterranean Region | 1 | 2017 | 276 | 0.04 | Why? |
| DNA Primers | 1 | 2020 | 1170 | 0.04 | Why? |
| Social Media | 1 | 2017 | 5798 | 0.04 | Why? |
| Treatment Refusal | 1 | 2017 | 211 | 0.04 | Why? |
| Insurance Coverage | 1 | 2019 | 348 | 0.03 | Why? |
| Chemokines | 1 | 2020 | 1095 | 0.03 | Why? |
| Retrospective Studies | 4 | 2019 | 105322 | 0.03 | Why? |
| Self Efficacy | 1 | 2020 | 717 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Italy | 1 | 2018 | 38444 | 0.03 | Why? |
| Prospective Studies | 2 | 2017 | 43301 | 0.03 | Why? |
| Eosinophils | 1 | 2020 | 848 | 0.03 | Why? |
| Mental Disorders | 1 | 2017 | 6742 | 0.03 | Why? |
| Streptococcus pneumoniae | 1 | 2018 | 827 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| Propensity Score | 1 | 2021 | 2690 | 0.03 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.03 | Why? |
| Life Expectancy | 1 | 2017 | 474 | 0.03 | Why? |
| Social Stigma | 1 | 2020 | 1049 | 0.03 | Why? |
| Hemagglutination Inhibition Tests | 1 | 2011 | 191 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Seroepidemiologic Studies | 2 | 2020 | 10017 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.03 | Why? |
| Saudi Arabia | 1 | 2021 | 4423 | 0.03 | Why? |
| Trust | 1 | 2020 | 1487 | 0.02 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Phenotype | 1 | 2020 | 4037 | 0.02 | Why? |
| Carrier State | 1 | 2021 | 2100 | 0.02 | Why? |
| Image Processing, Computer-Assisted | 1 | 2018 | 1383 | 0.02 | Why? |
| Neoplasms | 1 | 2017 | 17251 | 0.02 | Why? |
| Monocytes | 1 | 2020 | 2978 | 0.02 | Why? |
| Internationality | 1 | 2021 | 3297 | 0.02 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.02 | Why? |
| HEK293 Cells | 1 | 2020 | 8394 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2019 | 2782 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.02 | Why? |
| HIV Infections | 1 | 2011 | 11620 | 0.02 | Why? |
| Survivors | 1 | 2017 | 2619 | 0.02 | Why? |
| Geography | 1 | 2011 | 1801 | 0.02 | Why? |
| Caregivers | 1 | 2019 | 3112 | 0.02 | Why? |
| Research Design | 1 | 2021 | 5830 | 0.02 | Why? |
| Health Services Needs and Demand | 1 | 2019 | 3419 | 0.02 | Why? |
| Asia | 1 | 2011 | 2399 | 0.02 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.02 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.02 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.02 | Why? |
| Safety Management | 1 | 2011 | 1093 | 0.02 | Why? |
| Mass Media | 1 | 2011 | 837 | 0.01 | Why? |
| Homosexuality, Male | 1 | 2011 | 1158 | 0.01 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Phylogeny | 1 | 2020 | 13341 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Poverty | 1 | 2011 | 2302 | 0.01 | Why? |
| Hospitals | 1 | 2018 | 11793 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2021 | 9044 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |